Printer Friendly

VESTAR ISSUES STATEMENT REGARDING PATENT ISSUED TO LIPOSOME TECHNOLOGY, INC.

 SAN DIMAS, Calif., Jan. 19 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today issued the following statement in response to inquiries from the investment community:
 "We are aware of the U.S. patent issued to Liposome Technology, Inc. that was announced earlier today. The methodology described in this patent does not appear to be relevant to Vestar's product, AmBisome(R). This patent concerns a process for preventing the alteration in size of liposomes that enclose amphotericin B. It also describes increased toxicity when such size changes occur. We are very pleased to state that AmBisome does not change size before lyophilization (freeze drying) or after reconstitution back to a liquid solution, and therefore we do not need any process to prevent size changes. In fact, we believe the size stability of AmBisome is one of the reasons that the toxicity of our product is so low."
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds. Since 1989, Vestar has been marketing in Europe AmBisome, a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is in development as Vestar's second major product.
 -0- 1/19/93
 /CONTACT: Michael E. Hart, chief financial officer, of Vestar, Inc., 714-394-4119; or Marcia A. Kean, executive VP, of Feinstein Partners Inc., 617-577-8110, for Vestar/
 (VSTR)


CO: Vestar, Inc. ST: California IN: MTC SU:

SJ -- NE0017 -- 6449 01/19/93 14:41 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 19, 1993
Words:272
Previous Article:ZEOS INTERNATIONAL'S 486DX-33 SYSTEM IS NAMED PC WORLD'S BEST BUY; CITED AS 'FASTEST 33 MHZ 486DX TESTED'
Next Article:THERMO CARDIOSYSTEMS EXPRESSES REGRET IN DEATH OF HEART PATIENT
Topics:


Related Articles
ANIMAL DATA ON VESTAR'S DAUNOXOME SUPPORT EMERGING CLINICAL PROFILE AGAINST CANCER
VESTAR FILES COUNTERCLAIM VS. THE LIPOSOME COMPANY: ALLEGES THAT PATENT IS INVALID AND DENIES INFRINGEMENT
THE LIPOSOME COMPANY SUES VESTAR; SUIT CHARGES VESTAR'S AMBISOME INFRINGES LIPOSOME'S PATENT
VESTAR EXPRESSES CONFIDENCE IN PATENT POSITION; WILL VIGOROUSLY CONTEST ALL INFRINGEMENT ALLEGATIONS
VESTAR FILES SUIT AGAINST LIPOSOME TECHNOLOGY, INC.
COURT FINDS VESTAR DOES NOT INFRINGE LTI PATENT
NEXAGEN AND VESTAR SIGN MERGER AGREEMENT
LIPOSOME TECHNOLOGY, INC. ANNOUNCES JUDGMENT
The Liposome Company Receives Notice Of Allowance From U.S. Patent And Trademark Office Of Additional Patent For ABELCET
Valentis Receives Broad Patent Covering PEGylated Liposome Products.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters